Johnson & Johnson Maintains Steady Dividends While Eli Lilly Bets on the Weight-Loss Drug Track Oct 2, 2026 Life Science
Lilly and Viking Just Showed the Obesity Market’s Next Phase — and It’s Not About Pounds Sep 30, 2026 Life Science
Competition Fears Are Overblown, and Eli Lilly’s Growth Engine Remains Strong Sep 30, 2026 Life Science
Summit Secures $2 Billion Investment From AstraZeneca, and the Two Parties Will Jointly Develop Anti-Cancer Drugs Sep 28, 2026 Life Science
STAAR Surgical Announces $50 Million Buyback Plan, Stock Soars More Than 7% on Friday Sep 26, 2026 Life Science
Revolution Medicines Receives FDA Breakthrough Designation, Royalty Pharma Offers a Diversified Investment Path Sep 25, 2026 Life Science
AI Finds New Clues for Gene Editing, but It Is Still Far from a “New CRISPR” Sep 23, 2026 Life Science
Positive VK2735 Clinical Data: Can Viking Therapeutics Displace Eli Lilly and Novo Nordisk? Sep 23, 2026 Life Science
Apple Explores Screenless Health Tracker, Wearable Product Line May Face Major Overhaul Sep 22, 2026 Technology
Johnson & Johnson Accelerates Divestiture of DePuy Synthes, Investors Optimistic About Streamlined Strategy Sep 22, 2026 Life Science
Eli Lilly Stock Trails the Market, and Its Growth Story Faces a Test Under a High Valuation Sep 21, 2026 Life Science
Eli Lilly’s Leading Position in the Weight-Loss Drug Market Remains Solid, Competition Landscape for Oral Drugs Begins to Emerge Sep 19, 2026 Life Science
Johnson & Johnson vs. Kenvue, Which Is Better Suited for a Defensive Dividend Portfolio? Sep 17, 2026 Life Science
From the Financial Crisis to the 2022 Bear Market, How Does Amgen Demonstrate Resilience? Sep 17, 2026 Life Science
Investors Seek Buying Opportunities Before Year-End, These Two Stocks Are Cheaply Valued and Offer Growth Potential Sep 16, 2026 Financial Service, Life Science
